Nu-Med Plus, a medical device development company, announced the development of a new delivery system and formulation for the generation of inhaled nitric oxide for potential therapeutic use outside the hospital and
clinical environment. The newly developed system uses the thermal decomposition of a complex compound as the source of nitric oxide.
Nitric Oxide (NO) is an essential biological gas which is currently being used for congenital pulmonary hypoplasia and neonatal hypoxia therapy. Contemporary research is being done for additional applications involving the therapeutic need for vasodilation and increased delivery of oxygen to diseased and injured tissues. Jeff Robins, President and CEO of Nu-Med Plus said, “This newly developed Inhaled Nitric Oxide generation concept has vast potential for a very portable unit that could be used by an individual when there is an instantaneous and critical necessity for the administration of the gas.”
Nu-Med Plus
nu-medplus.com
